Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03380390 · ClinicalTrials.gov registry record · Phase 4
Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea
A Phase 4 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT03380390 is a Phase 4 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 46 participants.
The verdict
NCT03380390, a Phase 4 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.
Interventions
- DRUG Oxymetazoline HCL 1.0% Cream
- DEVICE Energy-Based Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-12-04 |
| Est. Completion | 2018-06-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03380390
The ClinicalTrials.gov registry entry for NCT03380390 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxymetazoline HCL 1.0% Cream is the first listed.
NCT03380390 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03380390 about?
NCT03380390 is a clinical study titled "Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea". This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.
What is the current status of trial NCT03380390?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2017-12-04. Estimated completion is 2018-06-15.
What interventions are being tested in trial NCT03380390?
The interventions under investigation include: Oxymetazoline HCL 1.0% Cream (DRUG), Energy-Based Therapy (DEVICE).
Who is sponsoring clinical trial NCT03380390?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.